Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorNavani, Vishal
dc.contributor.authorErnst, Matthew
dc.contributor.authorWells, Connor
dc.contributor.authorYuasa, Takeshi
dc.contributor.authorTakemura, Kosuke
dc.contributor.authorDonskov, Frede
dc.contributor.authorSuárez Rodríguez, Cristina
dc.date.accessioned2022-09-09T07:27:36Z
dc.date.available2022-09-09T07:27:36Z
dc.date.issued2022-06-01
dc.identifier.citationNavani V, Ernst M, Wells JC, Yuasa T, Takemura K, Donskov F, et al. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2022 Jun 1;5(6):e2216379.
dc.identifier.issn2574-3805
dc.identifier.urihttp://hdl.handle.net/11351/8086
dc.descriptionCombination Therapies; Metastatic Renal Cell Carcinoma
dc.description.abstractImportance The association between treatment with first-line immuno-oncology (IO) combination therapies and physician-assessed objective imaging response among patients with metastatic renal cell carcinoma (mRCC) remains uncharacterized. Objective To compare the likelihood of objective imaging response (ie, complete or partial response) to first-line IO combination ipilimumab-nivolumab (IOIO) therapy vs approved IO with vascular endothelial growth factor inhibitor (IOVE) combination therapies among patients with mRCC. Design, Setting, and Participants This multicenter international cohort study was nested in routine clinical practice. A data set from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) was used to identify consecutive patients with mRCC who received treatment with IO combination therapies between May 30, 2013, and September 9, 2021. A total of 899 patients with a histologically confirmed diagnosis of mRCC who received treatment with a first-line IOVE or IOIO regimen and had evaluable responses were included. Exposures Best overall response to first-line IO combination therapy based on Response Evaluation Criteria in Solid Tumors, version 1.1. Main Outcomes and Measures The primary outcome was the difference in treating physician–assessed objective imaging response based on the type of first-line IO combination therapy received. Secondary outcomes included the identification of baseline characteristics positively associated with objective imaging response and the association of objective imaging response with overall survival. Results Among 1085 patients with mRCC who received first-line IO combination therapies, 899 patients (median age, 62.8 years [IQR, 55.9-69.2 years]; 666 male [74.2%]) had evaluable responses. A total of 794 patients had information available on IMDC risk classification; of those, 127 patients (16.0%) had favorable risk, 442 (55.7%) had intermediate risk, and 225 (28.3%) had poor risk. With regard to best overall response among all participants, 37 patients (4.1%) had complete response, 344 (38.3%) had partial response, 315 (35.0%) had stable disease, and 203 (22.6%) had progressive disease. Corresponding median overall survival was not estimable (95% CI, 53.3 months to not estimable) among patients with complete response, 55.9 months (95% CI, 44.1 months to not estimable) among patients with partial response, 48.1 months (95% CI, 33.4 months to not estimable) among patients with stable disease, and 13.0 months (95% CI, 8.4-18.1 months) among patients with progressive disease (log rank P < .001). Treatment with IOVE therapy was found to be independently associated with an increased likelihood of obtaining response (OR, 1.89; 95% CI, 1.26-2.81; P = .002) compared with IOIO therapy. The presence of lung metastases (odds ratio [OR], 1.49; 95% CI, 1.01-2.20), receipt of cytoreductive nephrectomy (OR, 1.59; 95% CI, 1.04-2.43), and favorable IMDC risk (OR, 1.93; 95% CI, 1.10-3.39) were independently associated with an increased likelihood of response. Conclusions and Relevance In this study, treatment with IOVE therapy was associated with significantly increased odds of objective imaging response compared with IOIO therapy. The presence of lung metastases, receipt of cytoreductive nephrectomy, and favorable IMDC risk were associated with increased odds of experiencing objective imaging response. These findings may help inform treatment selection, especially in clinical contexts associated with high-volume multisite metastatic disease, in which obtaining objective imaging response is important.
dc.language.isoeng
dc.publisherAmerican Medical Association
dc.relation.ispartofseriesJAMA Network Open;5(6)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectRonyons - Càncer - Tractamemt
dc.subjectFactors de creixement
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subject.meshCarcinoma, Renal Cell
dc.subject.mesh/drug therapy
dc.subject.meshVascular Endothelial Growth Factor A
dc.subject.mesh/therapeutic use
dc.titleImaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1001/jamanetworkopen.2022.16379
dc.subject.decscarcinoma de células renales
dc.subject.decs/farmacoterapia
dc.subject.decsfactor A de crecimiento endotelial vascular
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttp://dx.doi.org/10.1001/jamanetworkopen.2022.16379
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Navani V, Ernst M] Tom Baker Cancer Centre, Department of Medical Oncology, University of Calgary, Calgary, Canada. [Wells JC] BC Cancer Agency, Vancouver, Canada. [Yuasa T] Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. [Takemura K] Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. [Donskov F] Department of Oncology, Aarhus University Hospital, Aarhus, Denmark. [Suarez C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid35687336
dc.identifier.wos000809213100005
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record